Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Wave Life Sciences (WVE) over the last 11 years, with Q3 2025 value amounting to $2.4 million.

  • Wave Life Sciences' Other Working Capital Changes fell 6884.2% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$96.2 million, marking a year-over-year decrease of 40010.92%. This contributed to the annual value of -$93.6 million for FY2024, which is 27226.66% down from last year.
  • Per Wave Life Sciences' latest filing, its Other Working Capital Changes stood at $2.4 million for Q3 2025, which was down 6884.2% from -$7.1 million recorded in Q2 2025.
  • Wave Life Sciences' 5-year Other Working Capital Changes high stood at $126.4 million for Q1 2023, and its period low was -$82.3 million during Q4 2024.
  • Its 5-year average for Other Working Capital Changes is -$4.0 million, with a median of -$1.8 million in 2021.
  • Over the last 5 years, Wave Life Sciences' Other Working Capital Changes had its largest YoY gain of 808282.83% in 2023, and its largest YoY loss of 370815.22% in 2023.
  • Over the past 5 years, Wave Life Sciences' Other Working Capital Changes (Quarter) stood at -$1.8 million in 2021, then surged by 54.39% to -$805000.0 in 2022, then plummeted by 890.19% to -$8.0 million in 2023, then crashed by 932.82% to -$82.3 million in 2024, then soared by 102.91% to $2.4 million in 2025.
  • Its Other Working Capital Changes was $2.4 million in Q3 2025, compared to -$7.1 million in Q2 2025 and -$9.2 million in Q1 2025.